Importance: Synaptic dysfunction has been implicated in schizophrenia. However, whether synaptic density is reduced during the earliest stages of psychosis, including clinical high-risk (CHR) states and first-episode psychosis (FEP) was unclear.
Objective: To investigate synaptic density in FEP and CHR, examine the impact of cannabis use, and assess associations with negative symptoms and gray matter microstructure.
Methods: In this cross-sectional study, antipsychotic-free or minimally exposed FEP participants, CHR individuals, and healthy controls underwent 90-minute [18F]SynVesT-1 PET imaging to quantify synaptic vesicle glycoprotein 2A (SV2A) binding. Gray matter microstructure was assessed using diffusion MRI, and cannabis use was confirmed by urine drug screening.
Results: Forty-nine participants were included (16 FEP, 17 CHR, 16 controls). Synaptic density differed significantly across groups, with lower SV2A binding in FEP and CHR than in controls. Cannabis users also showed lower synaptic density. Across groups, reduced SV2A binding was associated with greater negative symptom severity and lower neurite density.
Conclusions: Lower synaptic density is detectable during early stages of psychosis, including CHR, and are associated with negative symptoms and altered gray matter microstructure. These findings support synaptic dysfunction as an early feature of psychosis and highlight the need for longitudinal studies investigating the effects of cannabis.